Trial Profile
Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 26 Nov 2020 Results published in the AIDS
- 04 Dec 2019 Status changed from active, no longer recruiting to completed.
- 22 Nov 2019 Status changed from recruiting to active, no longer recruiting.